A5109439796- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Colorectal Cancer Treatments and Studies
- Head and Neck Cancer Studies
- Mycobacterium research and diagnosis
- Orthopaedic implants and arthroplasty
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Screening and Detection
- Adhesion, Friction, and Surface Interactions
- Nutrition, Genetics, and Disease
- Infrastructure Resilience and Vulnerability Analysis
- Climate Change and Sustainable Development
- Radiomics and Machine Learning in Medical Imaging
- Neuroendocrine Tumor Research Advances
- Meningioma and schwannoma management
- Bone health and osteoporosis research
- Polyomavirus and related diseases
- Tribology and Lubrication Engineering
- Multiple and Secondary Primary Cancers
- Hip and Femur Fractures
- Peptidase Inhibition and Analysis
Tohoku University
2025
University of Tokyo Hospital
2024
Niigata University
2022
National Cancer Center Hospital East
2022
Hirosaki University
2018-2020
Aomori Prefectural Central Hospital
2017-2019
Toshiba (Japan)
2009
Background: Total hip arthroplasty (THA) is a widely used surgical intervention for osteoarthritis (HOA), with rising demand driven by an aging population. Osteoporosis associated increased risks of bone loss and implant loosening after THA. While medications such as bisphosphonates denosumab have shown promise in mitigating these risks, the impact preoperative osteoporosis treatment on postoperative outcomes remains unclear. This study investigates effect stress shielding clinical THA...
Afatinib, a second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC), was approved in Japan 2014. This study evaluated clinical outcomes of afatinib real-world practice. Medical records patients who received advanced EGFR-mutant NSCLC were retrospectively reviewed. In total, 128 analyzed. Seventy-six as the first-line setting and 52 re-challenge (i.e., after failure prior first-generation TKI). There no difference...
Pembrolizumab has become the standard first-line treatment for non-small cell lung cancer (NSCLC) patients with high PD-L1expression. MET exon 14 skipping is a rare mutation typically found in older, female, and non-smoking NSCLC. Herein, we report case of 71-year-old woman who was diagnosed NSCLC left lung. EGFR ALK fusion were not detected. Because biopsy specimen showed PD-L1 expression tumor proportion score 95%, pembrolizumab introduced as therapy, but resulted no clinical benefit. The...
This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended of afatinib for II in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The study used a standard 3 + escalation design. Patients aged 75 years or older NSCLC EGFR mutations were enrolled. doses afatinib, which given once daily, planned as follows: level 1, 20 mg/day; 2, 30 3, 40 mg/day. Dose-limiting toxicity (DLT)...
The present retrospective study was conducted to evaluate the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring driver mutations. Patients NSCLC mutations who received ICIs (nivolumab or pembrolizumab) were reviewed Hirosaki University and Aomori Prefectural Central Hospital. There 139 molecular targeted drugs, including 24 treated ICIs. Patient characteristics as follows: Male/female, 5/19; median age 68 (range 39-82);...
A de novo single-nucleotide mutation in the EGFR gene can cause development of lung cancer. tyrosine kinase inhibitors (EGFR-TKIs) are used for clinical treatment such cancers, but acquired resistance often mitigates their efficacy. Accordingly, monitoring and nucleotide mutations is essential cancers with EGFR-TKIs. Previously, we reported that oligoribonucleotide interference-PCR (ORNi-PCR) accurately cost-effectively detect mutations. In this study, applied ORNi-PCR to simultaneous...
PPM1D, a protein Ser/Thr phosphatase, is overexpressed in various cancers and functions as an oncogenic by inactivating the p53 pathway. Therefore, molecules that bind PPM1D are expected to be useful anti-cancer agents. In this study, we constructed phage display library based on antibody-like small molecule adnectin screened for PPM1D-specific binding molecules. We identified two adnectins, PMDB-1 PMD-24, specific B-loop PPM1D430 targets, respectively. Specificity analyses of these...
7174 Background: Concurrent chemoradiation has been proposed as one of the best treatments for locally advanced NSCLC. However, optimal therapy NSCLC continues to evolve. This phase II trial was carried out evaluate response and toxicity regimen CBDCA weekly TXT combined with concurrent radiotherapy Methods: In a recent I trial, we explored feasibility radiochemotherapy TXT. The recommended doses were determined follows. CBDCA: AUC 5.0 d1, 29; TXT: 15 mg/m2 8, 15, 29, 36, 43, radiation total...
The accelerated development of lung cancer treatments has resulted in a single global study that is sufficient for new agent and indication to be approved. Not all predominate globally, differences standards care may influence the efficacy real world.The results from Japanese domestic trials included subset population patients were evaluated 18 genomic targeted agents immune therapies approved after 2000. collected drug applications reviewed treatment approval Japan.Japan one first countries...
In Japan, earthquake resistance improvement (earthquake proofing) of drinking water infrastructure is not as developed for other types such gas and electricity. To facilitate proofing, it important utilities to encourage customers better understand its importance effectiveness. So that consumers could instinctively the effectiveness we applied concept ‘recovery time expectancy’ an indicator treatment plants. this study, performed a recovery simulation medium-scale plant based on system...
e21173 Background: Afatinib is the second generation epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC), and approved in Japan 2014. This study evaluated clinical outcomes of afatinib real world practice. Methods: Patients who received advanced EGFR-mutant NSCLC 5 institutions Aomori, from October 2014 to January 2017 were included into analyses. Results: In total, 128 patients analyzed. Seventy-six as first-line setting 52...